- In August 2022, Processa Pharmaceuticals, Inc. initiated its Phase 2A clinical trial for PCS12852, enrolling its first patient with moderate to severe gastroparesis
- In February 2022, Vanda Pharmaceuticals Inc. (Vanda) shared the Phase III clinical trial outcomes, VP-VLY-686-3303, revealing the effectiveness and safety of tradipitant in addressing gastroparesis symptoms
Frequently Asked Questions
The U.S. is expected to dominate the global gastroparesis market, particularly in the North America region. This dominance is attributed to high healthcare spending and a large population suffering from diabetic gastroparesis.
The major factors driving the growth of the gastroparesis market are the rising prevalence of diabetes, increasing adoption of new drug therapies, and advancements in surgical procedures.
The primary challenges include the high cost of treatment and drugs, limited awareness in developing countries, and a lack of standardized treatment protocols for gastroparesis.
The diabetic gastroparesis segment is expected to dominate the global gastroparesis market, holding a significant market share in 2025 due to the strong correlation between diabetes and gastroparesis, along with the rising global incidence.
